Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

4/4/24 6:23:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALDX alert in real time by email

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Aldeyra Therapeutics

The Trade: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 10% owner Joseph Edelman acquired a total of 504,272 shares an average price of $3.84. To acquire these shares, it cost around $1.93 million.
What’s Happening: On April 3, Oppenheimer upgraded the stock from Perform to Outperform and announced a $10 price target.
What Aldeyra Therapeutics Does: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.

Retractable Technologies

The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw acquired a total of 8,292 shares at at an average price of $1.15. To acquire these shares, it cost around $9,499.
What’s Happening: On March 29, Retractable Technologies reported results for 2023.
What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.

Check This Out: Levi Strauss, Conagra Brands And 3 Stocks To Watch Heading Into Thursday

Alzamend Neuro

The Trade: Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton C Ault III acquired a total of 334 shares at an average price of $0.91. The insider spent around $304 to buy those shares.
What’s Happening: On Dec. 11, 2023, Alzamend Neuro received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD).
What Alzamend Neuro Does: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's.

Don’t forget to check out our premarket coverage here

Get the next $ALDX alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ALDX
$ALZN
$RVP

Company	Date	Price Target	Rating	Analyst
Aldeyra Therapeutics Inc. $ALDX	4/3/2024	$10.00	Perform → Outperform	Oppenheimer
Aldeyra Therapeutics Inc. $ALDX	4/2/2024	$10.00	Buy	H.C. Wainwright
Aldeyra Therapeutics Inc. $ALDX	4/27/2022	$15.00	Buy	H.C. Wainwright
Aldeyra Therapeutics Inc. $ALDX	12/21/2021	$25.00 → $21.00	Buy	Citigroup
Aldeyra Therapeutics Inc. $ALDX	12/21/2021	$24.00 → $15.00	Outperform	SVB Leerink
Alzamend Neuro Inc. $ALZN	10/1/2021	$8.00	Buy	Ascendiant Capital Markets

More analyst ratings

$ALDX
$ALZN
$RVP
Press Releases

Fastest customizable press release news feed in the world

Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Dr. Brady's conversation with Andreas Argyrides, Managing Director, Senior Biotech Analyst at Oppenheimer & Co. Inc., is scheduled to begin at 10:40 a.m. ET Wednesday, February 25, 2026. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the

2/18/26 7:01:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retractable Technologies, Inc. ("Retractable") (NYSE:RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning October 1, 2025 through December 31, 2025. The dividends will be paid on January 20, 2026 to shareholders of record as of the close of business on January 10, 2026. Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and

12/30/25 4:14:00 PM ET

Medical/Dental Instruments

Health Care

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. Following submission on June 16, 2025, the NDA was accepted for review as a "complete class 2 response" by the FDA on July 16, 2025, with a target PDUFA action date of December 16, 2025. On December 12, 2025, the FDA met with Aldeyra to r

12/15/25 7:30:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$ALDX
$ALZN
$RVP
Financials

Live finance-specific insights

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retractable Technologies, Inc. ("Retractable") (NYSE:RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning October 1, 2025 through December 31, 2025. The dividends will be paid on January 20, 2026 to shareholders of record as of the close of business on January 10, 2026. Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and

12/30/25 4:14:00 PM ET

Medical/Dental Instruments

Health Care

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. Following submission on June 16, 2025, the NDA was accepted for review as a "complete class 2 response" by the FDA on July 16, 2025, with a target PDUFA action date of December 16, 2025. On December 12, 2025, the FDA met with Aldeyra to r

12/15/25 7:30:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and development webcast the expansion of the RASP platform to include programs in central nervous system diseases associated with inflammation, and provided updated manufacturing information on reproxalap. Based on new preclinical results in models of Parkinson's disease and amyotrophic lateral sclerosis, which included improved grip strength, balance, and biomarkers of central nervous system function, potential clinical indications for the orally administered, next-generation RASP

11/13/25 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$ALDX
$ALZN
$RVP
Leadership Updates

Live Leadership Updates

Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

4/17/25 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen

4/4/22 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Retractable Technologies, Inc. Declares Dividends to Series I and II Class B Convertible Preferred Stock Shareholders

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series I Class B and Series II Class B Convertible Preferred Stock in the amounts of $10,041 and $39,050, respectively. Over the entire accrual period, the dividend amount is $0.125 per share for Series I Class B shareholders and $0.25 per share for Series II Class B shareholders. Dividends have accrued at 10% per annum and cover amounts in arrears from October 1, 2020 through date of conversion or December 31, 2020 whichever is applicable. The dividends will be paid on January 29, 2021. All Series I Class B Conv

1/8/21 2:32:00 PM ET

Medical/Dental Instruments

Health Care